IQVIA Holdings Inc. (0JDM.L)
USD 153.88
(1.18%)
USD 153.88
(1.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.35 Billion USD | 24.47% |
| 2022 | 1.09 Billion USD | 12.94% |
| 2021 | 966 Million USD | 246.24% |
| 2020 | 279 Million USD | 46.07% |
| 2019 | 191 Million USD | -26.25% |
| 2018 | 259 Million USD | -80.21% |
| 2017 | 1.3 Billion USD | 1038.26% |
| 2016 | 115 Million USD | -70.3% |
| 2015 | 387.2 Million USD | 8.65% |
| 2014 | 356.38 Million USD | 57.28% |
| 2013 | 226.59 Million USD | 27.62% |
| 2012 | 177.54 Million USD | -26.56% |
| 2011 | 241.77 Million USD | 50.55% |
| 2010 | 160.59 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 285 Million USD | -21.49% |
| 2024 Q1 | 288 Million USD | -38.59% |
| 2024 Q2 | 363 Million USD | 26.04% |
| 2023 Q4 | 469 Million USD | 54.79% |
| 2023 Q3 | 303 Million USD | 2.02% |
| 2023 Q1 | 289 Million USD | 27.31% |
| 2023 Q2 | 297 Million USD | 2.77% |
| 2023 FY | 1.35 Billion USD | 24.47% |
| 2022 Q3 | 283 Million USD | 10.55% |
| 2022 Q1 | 325 Million USD | 2.2% |
| 2022 Q4 | 227 Million USD | -19.79% |
| 2022 Q2 | 256 Million USD | -21.23% |
| 2022 FY | 1.09 Billion USD | 12.94% |
| 2021 Q1 | 212 Million USD | 78.15% |
| 2021 Q2 | 175 Million USD | -17.45% |
| 2021 Q3 | 261 Million USD | 49.14% |
| 2021 FY | 966 Million USD | 246.24% |
| 2021 Q4 | 318 Million USD | 21.84% |
| 2020 Q1 | 82 Million USD | 412.5% |
| 2020 Q4 | 119 Million USD | 17.82% |
| 2020 Q2 | -23 Million USD | -128.05% |
| 2020 Q3 | 101 Million USD | 539.13% |
| 2020 FY | 279 Million USD | 46.07% |
| 2019 Q1 | 58 Million USD | -15.94% |
| 2019 FY | 191 Million USD | -26.25% |
| 2019 Q2 | 60 Million USD | 3.45% |
| 2019 Q3 | 57 Million USD | -5.0% |
| 2019 Q4 | 16 Million USD | -71.93% |
| 2018 Q1 | 69 Million USD | -93.59% |
| 2018 FY | 259 Million USD | -80.21% |
| 2018 Q4 | 69 Million USD | 15.0% |
| 2018 Q3 | 60 Million USD | -1.64% |
| 2018 Q2 | 61 Million USD | -11.59% |
| 2017 Q2 | 62 Million USD | -16.22% |
| 2017 Q1 | 74 Million USD | 141.57% |
| 2017 Q4 | 1.07 Billion USD | 1122.73% |
| 2017 Q3 | 88 Million USD | 41.94% |
| 2017 FY | 1.3 Billion USD | 1038.26% |
| 2016 Q1 | 107 Million USD | 2.32% |
| 2016 Q3 | 100 Million USD | 16.28% |
| 2016 Q2 | 86 Million USD | -19.63% |
| 2016 FY | 115 Million USD | -70.3% |
| 2016 Q4 | -178 Million USD | -278.0% |
| 2015 FY | 387.2 Million USD | 8.65% |
| 2015 Q4 | 104.57 Million USD | -6.03% |
| 2015 Q3 | 111.28 Million USD | 31.0% |
| 2015 Q2 | 84.95 Million USD | -1.67% |
| 2015 Q1 | 86.39 Million USD | -2.29% |
| 2014 Q4 | 88.42 Million USD | -4.56% |
| 2014 Q3 | 92.65 Million USD | 8.85% |
| 2014 Q1 | 90.18 Million USD | 23.55% |
| 2014 FY | 356.38 Million USD | 57.28% |
| 2014 Q2 | 85.12 Million USD | -5.61% |
| 2013 Q3 | 66.76 Million USD | 73.35% |
| 2013 Q4 | 72.99 Million USD | 9.33% |
| 2013 FY | 226.59 Million USD | 27.62% |
| 2013 Q1 | 48.3 Million USD | 38.13% |
| 2013 Q2 | 38.51 Million USD | -20.27% |
| 2012 Q1 | 43.27 Million USD | 0.0% |
| 2012 Q3 | 52.09 Million USD | 10.37% |
| 2012 Q4 | 34.97 Million USD | -32.87% |
| 2012 FY | 177.54 Million USD | -26.56% |
| 2012 Q2 | 47.2 Million USD | 9.08% |
| 2011 FY | 241.77 Million USD | 50.55% |
| 2010 FY | 160.59 Million USD | 0.0% |
| 2001 Q3 | 283 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 540.226% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 2606.09% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 1634.793% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 485.699% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 591.804% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 1245.866% |
| Imunon, Inc. | -19.51 Million USD | 7058.758% |
| Dynavax Technologies Corporation | -6.38 Million USD | 21355.283% |
| Editas Medicine, Inc. | -153.21 Million USD | 986.313% |
| FibroGen, Inc. | -284.23 Million USD | 577.779% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 405.83% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 3318.086% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -443.853% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 353.369% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -103091.489% |
| Verastem, Inc. | -87.36 Million USD | 1654.363% |
| Zoetis Inc. | 2.34 Billion USD | 42.065% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 62.482% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 626.702% |
| Homology Medicines, Inc. | -53.74 Million USD | 2626.841% |
| Nektar Therapeutics | -276.05 Million USD | 591.929% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 1681.0% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 3506.924% |
| Perrigo Company plc | -12.7 Million USD | 10792.913% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 748.991% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 115.725% |
| Illumina, Inc. | -1.16 Billion USD | 216.968% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 77.348% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 1328.303% |
| Waters Corporation | 642.23 Million USD | -111.449% |
| Biogen Inc. | 1.16 Billion USD | -16.958% |
| Evolus, Inc. | -61.68 Million USD | 2301.508% |
| Adicet Bio, Inc. | -142.65 Million USD | 1051.927% |
| bluebird bio, Inc. | -211.91 Million USD | 740.829% |
| Geron Corporation | -184.12 Million USD | 837.534% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 408.467% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 995.873% |
| Myriad Genetics, Inc. | -112 Million USD | 1312.5% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 382.216% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -72.165% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 3144.617% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -710.045% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 65.652% |
| Agilent Technologies, Inc. | 1.24 Billion USD | -9.516% |
| OPKO Health, Inc. | -188.86 Million USD | 819.04% |
| Exelixis, Inc. | 207.76 Million USD | -553.623% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -1179.442% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 2958.646% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 667.636% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 470.749% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -382.255% |
| Blueprint Medicines Corporation | -506.98 Million USD | 367.859% |
| Insmed Incorporated | -749.56 Million USD | 281.171% |
| TG Therapeutics, Inc. | 12.67 Million USD | -10616.54% |
| Incyte Corporation | 597.59 Million USD | -127.243% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 278.567% |